|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.97 CNY | +3.16% |
|
+8.50% | -16.28% |
Vcanbio Cell & Gene Engineering Corp., Ltd reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 768.8 million compared to CNY 768.1 million a year ago. Net income was CNY 64.83 million compared to CNY 110.7 million a year ago.
Basic earnings per share from continuing operations was CNY 0.14 compared to CNY 0.24 a year ago. Diluted earnings per share from continuing operations was CNY 0.14 compared to CNY 0.24 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.28% | 1.06B | |
| +1.69% | 12.8B | |
| -7.57% | 7.61B | |
| +3.22% | 5.41B | |
| +0.93% | 4.51B | |
| +8.48% | 4.49B | |
| +9.21% | 2.73B | |
| -13.87% | 2.02B | |
| -11.63% | 1.73B | |
| +3.45% | 1.64B |
VCANBIO CELL & GENE ENGINEERING CORP., LTD 
